1. Home
  2. MIRM vs SKYW Comparison

MIRM vs SKYW Comparison

Compare MIRM & SKYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • SKYW
  • Stock Information
  • Founded
  • MIRM 2018
  • SKYW 1972
  • Country
  • MIRM United States
  • SKYW United States
  • Employees
  • MIRM N/A
  • SKYW N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • SKYW Air Freight/Delivery Services
  • Sector
  • MIRM Health Care
  • SKYW Consumer Discretionary
  • Exchange
  • MIRM Nasdaq
  • SKYW Nasdaq
  • Market Cap
  • MIRM 3.8B
  • SKYW 4.2B
  • IPO Year
  • MIRM 2019
  • SKYW N/A
  • Fundamental
  • Price
  • MIRM $69.89
  • SKYW $95.88
  • Analyst Decision
  • MIRM Strong Buy
  • SKYW Strong Buy
  • Analyst Count
  • MIRM 11
  • SKYW 4
  • Target Price
  • MIRM $79.00
  • SKYW $126.75
  • AVG Volume (30 Days)
  • MIRM 580.7K
  • SKYW 256.1K
  • Earning Date
  • MIRM 11-04-2025
  • SKYW 10-30-2025
  • Dividend Yield
  • MIRM N/A
  • SKYW N/A
  • EPS Growth
  • MIRM N/A
  • SKYW 132.99
  • EPS
  • MIRM N/A
  • SKYW 9.81
  • Revenue
  • MIRM $429,161,000.00
  • SKYW $3,840,870,000.00
  • Revenue This Year
  • MIRM $53.14
  • SKYW $16.22
  • Revenue Next Year
  • MIRM $19.83
  • SKYW $3.54
  • P/E Ratio
  • MIRM N/A
  • SKYW $9.85
  • Revenue Growth
  • MIRM 62.33
  • SKYW 20.45
  • 52 Week Low
  • MIRM $36.88
  • SKYW $74.70
  • 52 Week High
  • MIRM $78.55
  • SKYW $135.57
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 43.37
  • SKYW 34.66
  • Support Level
  • MIRM $68.34
  • SKYW $98.74
  • Resistance Level
  • MIRM $71.86
  • SKYW $101.68
  • Average True Range (ATR)
  • MIRM 2.36
  • SKYW 2.44
  • MACD
  • MIRM -0.43
  • SKYW 0.04
  • Stochastic Oscillator
  • MIRM 28.92
  • SKYW 8.79

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About SKYW SkyWest Inc.

SkyWest Inc offers commercial air services in the United States, Canada, Mexico, and the Caribbean. Additionally, it leases aircraft to capable users to help generate revenue. Generally, SkyWest provides regional flights, and utilizes its smaller, lower-cost aircraft to carry passengers that booked tickets through airlines. It partners with carriers across the world to fly and operate aircraft for a fee. SkyWest may use the carriers's brand and ground support to coordinate marketing and easily transport passengers. The company has two reportable segments: SkyWest Airlines, which generates maximum revenue, and SkyWest Leasing.

Share on Social Networks: